ClinicalTrials.gg
CompletedNCT02902861METOPUpdated Sep 16, 2016

Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)

A Phase 3 interventional study of Methotrexate and Placebo ( for Methotrexate) in Psoriasis Vulgaris, sponsored by Prof. Kristian Reich. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-16.

Sponsored by Prof. Kristian Reich · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing methotrexate in Psoriasis — 8 open to participants now, 8 under way, none of them phase 3. Methotrexate · Psoriasis.

Enrollment
6th of 31
120 · median 60
Started
2013
with 2 others
Phase 3
6 of 31
none open now
Registered
16th of 31
by date

Among the 31 studies testing methotrexate in Psoriasis, this one is the 6th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 3, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 31 studies testing methotrexate in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing methotrexate in Psoriasis, or all of them as a file.
02

Study summary

This is a multicenter, multinational (12 centers planned, in Germany 9 centers and in France, the Netherlands and the United Kingdom (UK) 1 center in each country respectively), randomized, double-blinded, placebo-controlled study. The primary objective is to evaluate the efficacy of methotrexate (MTX) in patients with moderate to severe Psoriasis compared to Placebo as assessed by the primary endpoint "75% reduction of Psoriasis Area Severity Index" (PASI 75 ) during a 16 week treatment phase. As secondary objectives the safety and efficacy of the optimized treatment schedule will be assessed using multiple methods (e.g. (Serious) Adverse Events ((S)AE) occurrence and questionnaires)

Read the detailed description

The present study was initiated to further increase the knowledge about the optimal dosing regimen and to thus optimize the efficacy and safety of MTX treatment for patients with moderate to severe psoriasis. In view of the described risk-benefit profile of MTX, an initial dose of at least 15 mg per week administered subcutaneously followed by 5 mg folic acid p.o. 24 hours after MTX application seems appropriate. Since 20 mg MTX per week has been proven to be beneficial in a considerable part of patients, who did not respond sufficiently to 15 mg MTX per week, in this study the dosing starts with a dose of 17.5 mg MTX per week, administered subcutaneously. At such a starting dose, it was expected to find the highest MTX efficacy possible, but with appropriate safety margins. If in a patient, a "50% reduction of Psoriasis Area Severity Index" PASI50 response is not achieved in week 8, the dose will be increased to 22.5 mg MTX per week. All dosages used in this study lay within the approved dosing range of MTX. The study will be conducted in a double-blind, placebo controlled manner. Placebo was chosen as control since only this comparator allows a reliable interpretation of safety and efficacy data.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 18 years of age or older at time of ; may be men or women.
  2. Are MTX naïve
  3. Moderate to severe plaques psoriasis (according rule of ten (PASI ≥10 or BSA ≥ 10 or DLQI ≥ 10) for at least 6 months with or without psoriatic arthritis (however, highly active psoriatic arthritis is excluded, defined by. > 5 swollen tender joints or soles and C-Reactive Protein (CRP) >2 x UNL) .
  4. Women of and all men must be using a highly effective method of (pearl index \< 1%) as defined blow and must agree to continue to use such measures and not become pregnant or plan a pregnancy until 6 months after receiving the last injection of Medicinal Product (IMP).Highly effective method is defined as: Use of oral, injected or implanted hormonal methods, intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
  5. Able to adhere to the study visit schedule and other protocol requirements.
  6. Capable of giving informed consent. The informed consent must be obtained prior to any study related procedures.
  7. Must avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during study.
  8. Must agree not to receive a live virus or live bacterial vaccination 4 weeks prior to the first IMP s.c. administration, during the trial and up to 3 months after the last injection.
  9. Chest X-ray investigation within the last 6 months prior to first s.c. administration of IMP and show no abnormalities

Exclusion criteria

Exclusion Criteria:

  1. Currently have non-plaque forms of psoriasis (eg, erythrodermic, guttate, or pustular).
  2. Have current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, (hydroxy-) chloroquine, or lithium).
  3. Are pregnant, nursing, or planning pregnancy (both men and women) while enrolled in the study.
  4. Have screening laboratory test results for the following parameters outside the stated ranges (please refer also to :

    1. \< 10 g/dL
    2. White blood cells \< 3.0 x 109/L
    3. Neutrophils \< 1.5 x 109/L
    4. \< 100 x 109/L
    5. (calculated according to Cockcroft-Gault) \< 50 mL/min)
    6. (AST), Alanine Aminotransferase (ALT), and Gamma Glutamyltransferase (γ-GT) levels must be > 2 times the
    7. > 5mg/dl (85,5 μmol/l)
    8. Hypalbuminemia \<3,5 g/dl
  5. Have used any other IMP within the previous 4 weeks or 5 times the half-life of an agent prior to the first s.c. administration of the IMP of this study, whichever is longer.
  6. Not able or willing to wash out any prohibited medications as listed below.

    • Any biologics; 5 times of half-life
    • Phototherapy or any systemic medications that could affect the psoriasis (including but not limited to oral or injectable , retinoids, 1,25 dihydroxy vitamin D3 and analogues, sulfasalazine, hydroxyurea, or fumaric acid derivates), within 4 weeks
    • Any topical medications that could affect the psoriasis (e.g. corticosteroids, anthralin, calcipotriene, topical vitamin D derivates, retinoids, tazarotene), within 2 weeks
    • Any systemic (e.g. azathioprine, cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, and tacrolimus) ,within 4 weeks
    • lithium, antimalarial agents To be stopped directly prior to first s.c. administration of IMP
    • Intramuscular gold ,Within 4 weeks Patients who take prohibited medications that cannot be washed out within 4 weeks or at least 5 times of the half-life of the investigational agent prior to first s.c.

    administration of IMP should not be asked to participate in the trial.

  7. Have a history of chronic or recurrent infectious disease or had a serious infection or have been hospitalized or received i.v. antibiotics for the treatment of an infection within 2 months prior to screening.
  8. History of radiotherapy or planed concomitant radiotherapy
  9. Ulcers of the oral cavity (e.g. ulcerative stomatitis) and/or known gastrointestinal ulcer disease
  10. A known B12/cobalamin deficiency
  11. Known diagnosed ascites or pleural effusions
  12. Have a history of latent or active Tuberculosis (TB) (prior to screening).
  13. Have current signs or symptoms of severe, progressive, or uncontrolled renal (specifically with calculated creatinine clearance \< 20), hepatic (especially with bilirubin > 5mg/dl (85,5 mol/l), hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease.
  14. Have any known or have a history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to the first administration of study agent).
  15. Have shown a previous immediate response, including anaphylaxis, to the folic acid
  16. Are unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins.
  17. Are known to have had a substance abuse (drug or alcohol) problem within the previous 12 months.
  18. Staff or relatives/partner of any clinical research site
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    methotrexate

    Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.

    Drug: Methotrexate

  • Placebo comparator
    Placebo (NaCl-Solution)

    Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.

    Drug: Placebo ( for Methotrexate)

Interventions

  • methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg

    Also known as: MTX

  • DrugPlacebo ( for Methotrexate)

    NaCl-Solution manufactured to mimic Methotrexate

06

What researchers measure

Primary outcomes

  1. Difference in 75% reduction of Psoriasis Area Severity Index (PASI75) responder rate between treatment arms

    Time frame: week 16

Secondary outcomes

  1. Difference in PASI75 responder rate between treatment arms

    Time frame: weeks 52

  2. Difference in 50% reduction of Psoriasis Area Severity Index (PASI50)

    Time frame: weeks 15 and 52

  3. Difference in 90% reduction of Psoriasis Area Severity Index (PASI90)

    Time frame: weeks 15 and 52

  4. PASI75 in placebo arm (cross-over)

    Time frame: weeks 32

  5. Difference in Nail Psoriasis Severity Index (NAPSI)

    Time frame: weeks 16 and 52

  6. Difference in Body Surface Area Index (BSA)

    Time frame: weeks 16 and 52

  7. Difference in Physician's Global Assessment (PGA)

    Time frame: weeks 16 and 52

  8. Difference in Psoriatic Arthritis Index (PsA)

    Time frame: weeks 16 and 52

  9. Difference in Patient's satisfaction with metex® pre-filled syringe (PSAT metex®)

    Time frame: weeks 16 and 52

  10. Difference in Dermatology Life Quality Index (DLQI)

    Time frame: weeks 16 and 52

  11. Difference in European Qualification-5D-Questionnaire (EQ-5D)

    Time frame: weeks 16 and 52

  12. Safety and tolerability assessed by Adverse Events (AE)/ Serious Adverse Events (SAE) tolerability at the site of administration

    Time frame: week 0 - week 51

  13. Safety and tolerability assessed by laboratory values

    Time frame: week 0 - week 51

  14. local tolerability at the site of administration assessed by Erythema

    Erythema (redness): diameter (mm) and severity from none to severe (0 = none, 1= mild, 2 = moderate 3 = severe)

    Time frame: week 0 - week 51

  15. local tolerability at the site of administration assessed by Swelling

    Swelling/Induration: diameter (mm) and severity from none to severe (0 = none, 1= mild, 2 = moderate 3 = severe)

    Time frame: week 0 - week 51

  16. local tolerability at the site of administration assessed by Hematoma

    Hematoma: yes/ no and if present diameter (mm)

    Time frame: week 0 - week 51

  17. local tolerability at the site of administration assessed by Local Pain

    Local pain - assessed by the study subject on a visual analogue scale (1-10)

    Time frame: week 0 - week 51

  18. local tolerability at the site of administration assessed by Pruritus

    Pruritus - assessed by the study subject on a visual analogue scale (1-10)

    Time frame: week 0 - week 51

  19. Changes of levels of molecular biologic analysis

    Time frame: at baseline and 16 weeks

07

Study locations

1 site
  • Psoriasis-Zentrum, Universitäts-Hautklinik Kiel
    Kiel, Schleswig-Holstein 24105, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Sep 2014 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2016
First posted
Sep 16, 2016
Start
Feb 2013
Primary completionActual
Sep 2014
CompletionActual
May 2015
Last update
Sep 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02902861
Lead sponsor
Prof. Kristian Reich
Responsible party
Prof. Kristian Reich (Professor, Sciderm GmbH) — Sponsor-investigator
First posted
Sep 16, 2016
Start date
Feb 2013
Primary completion
Sep 2014
Completion
May 2015
Last update
Sep 16, 2016

Study contacts

Ulrich Mrowietz, Professor
principal investigator · Psoriasis-Zentrum, Universitäts-Hautklinik Kiel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion